Investee Company News

October 18, 2017 Novan Acquires IP Rights to Treat Viral Malignancies with Nitric Oxide October 13, 2017 Novan Announces Corporate Update Conference Call and Webcast October 10, 2017 Melinta Therapeutics’ Topical Radezolid Well Tolerated in Phase 1 Study for Treatment of Acne October 5, 2017 Poseida Therapeutics Presents Preclinical Solid Tumor Data for P-PSMA-101, a CAR-T Therapy Predominantly Comprised of Stem Cell Memory T Cells, at the Prostate Cancer Foundation Annual Retreat October 4, 2017 Melinta Therapeutics Presents Outcomes of Baxdela Treatment of Gram-Positive and Gram-Negative Pathogens at IDWeek October 4, 2017 Immunocore Appoints Andrew Hotchkiss as Chief Commercial Officer September 28, 2017 Cempra and Melinta Announce Expiration of Hart-Scott-Rodino Waiting Period for Proposed Merger September 26, 2017 Poseida Therapeutics Opens Enrollment in a Phase 1 Study of BCMA-Specific CAR-T Stem Cell Memory Therapy for Patients with Multiple Myeloma September 26, 2017 Melinta Therapeutics Provides for Distribution of Delafloxacin to 19 Countries via Extended Agreement with Eurofarma Laboratórios September 26, 2017 Machelle Sanders Appointed to Novan Board of Directors September 25, 2017 Novan Conducts Guidance Meeting with FDA on SB204 Development Program September 25, 2017 Melinta Therapeutics Presenting Detailed Analyses from Baxdela Phase 3 ABSSSI Trials and In Vitro Performance against Isolates of Resistant CABP and other Infections September 22, 2017 Melinta Therapeutics to Participate in Two Upcoming Investor Conferences September 21, 2017 Kymab and Seattle Children’s Research Institute publish impressive results using Kymab’s KY1005 in a model of Acute Graft versus Host Disease (aGVHD) in Science Translational Medicine September 18, 2017 Melinta Therapeutics Publication Highlights Baxdela Activity Against Fluoroquinolone-Non-Susceptible MRSA Pathogens September 18, 2017 Immunocore and the Bill & Melinda Gates Foundation Collaborate to Develop Immunotherapies for Infectious Diseases September 6, 2017 Poseida Therapeutics Presents Novel BCMA-Specific CAR-T Therapy at CAR-TCR Summit August 16, 2017 Novan Appoints Paula Brown Stafford, Chief Development Officer, to Board of Directors August 11, 2017 Phase 2b Results of Viamet’s Oral VT-1161 for the Treatment of Recurrent Vulvovaginal Candidiasis Presented at IDSOG Annual Meeting August 9, 2017 Cempra and Melinta Announce Merger to Form Leading, Vertically Integrated Commercial-Stage Anti-Infectives Company August 8, 2017 Data on Viamet’s VT-1161 for Treatment of RVVC to be Presented at IDSOG Annual Meeting July 31, 2017 Kymab Announces Clinical Update on its promising new antibody KY1005 for treatment of autoimmune diseases July 27, 2017 Viamet to Present Data on VT-1161 for the Treatment of Onychomycosis at the APMA Annual Meeting July 25, 2017 Novan Announces Corporate Update Conference Call and Webcast July 13, 2017 FDA Grants Fast Track Designation to VT-1598 for Treatment of Valley Fever July 13, 2017 Surgical Specialty Center of Baton Rouge is First Hospital in Southern Louisiana to Enhance Patient Safety by Deploying a Xenex LightStrike Germ-Zapping Robot July 7, 2017 Novan to Present Safety and Efficacy Data for SB204 Program in Adolescents at 13th World Congress of Pediatric Dermatology July 7, 2017 Immunocore and MEPC announce significant laboratory expansion at Milton Park in Oxfordshire, UK July 3, 2017 Immunocore announces third oncology target selected in discovery collaboration with GlaxoSmithKline June 29, 2017 Melinta Signs $90 Million Financing Agreement with Oberland Capital to Fund Baxdela™ Commercial Activities and Expansion into Additional Indications